Email Updates

You are here

AVAC in the News

  • Nearly four years after political pressure shut down two trials that would have tested whether a once-a-day pill could prevent high-risk HIV-negative people from catching the AIDS-causing virus, there’s a surge of renewed interest in the concept, known as Pre-Exposure Prophylaxis, or PrEP.

    December 1, 2008
    Scientific American
  • Since a study by Bailey in 2006 found the operation drops the HIV infection rate in men by 60 percent, the procedure most often performed at birth has become a popular elective surgery among grown men in southern Africa.

    July 31, 2008
  • The trial, called PAVE 100, would have tested whether a vaccine could help control HIV infection. The vaccine regimen was developed by the NIAID’s Vaccine Research Center and comprised a DNA vaccine containing HIV genes, with a modified cold virus carrying HIV genes as a booster.

    July 18, 2008
  • The US National Institutes of Health scrubbed plans to test its AIDS vaccine due to concerns about its safety and effectiveness, 10 months after the collapse of a clinical trial for a similar vaccine from Merck & Co.

    July 18, 2008
    Wall Street Journal